EP2331089A4 - Uses of sesquiterpene derivatives - Google Patents

Uses of sesquiterpene derivatives

Info

Publication number
EP2331089A4
EP2331089A4 EP08876930A EP08876930A EP2331089A4 EP 2331089 A4 EP2331089 A4 EP 2331089A4 EP 08876930 A EP08876930 A EP 08876930A EP 08876930 A EP08876930 A EP 08876930A EP 2331089 A4 EP2331089 A4 EP 2331089A4
Authority
EP
European Patent Office
Prior art keywords
sesquiterpene derivatives
sesquiterpene
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08876930A
Other languages
German (de)
French (fr)
Other versions
EP2331089B1 (en
EP2331089A2 (en
Inventor
Tae-Sun Park
Ha-Won Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kwang Dong Pharmaceutical Co Ltd
Original Assignee
Kwang Dong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwang Dong Pharmaceutical Co Ltd filed Critical Kwang Dong Pharmaceutical Co Ltd
Publication of EP2331089A2 publication Critical patent/EP2331089A2/en
Publication of EP2331089A4 publication Critical patent/EP2331089A4/en
Application granted granted Critical
Publication of EP2331089B1 publication Critical patent/EP2331089B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
EP08876930.2A 2008-09-11 2008-10-20 Uses of sesquiterpene derivatives Active EP2331089B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080089971A KR100905419B1 (en) 2008-09-11 2008-09-11 Uses of sesquiterpene derivatives
PCT/KR2008/006198 WO2010030054A2 (en) 2008-09-11 2008-10-20 Uses of sesquiterpene derivatives

Publications (3)

Publication Number Publication Date
EP2331089A2 EP2331089A2 (en) 2011-06-15
EP2331089A4 true EP2331089A4 (en) 2011-12-21
EP2331089B1 EP2331089B1 (en) 2015-12-16

Family

ID=41337139

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08876930.2A Active EP2331089B1 (en) 2008-09-11 2008-10-20 Uses of sesquiterpene derivatives

Country Status (9)

Country Link
US (1) US8481592B2 (en)
EP (1) EP2331089B1 (en)
JP (1) JP5435375B2 (en)
KR (1) KR100905419B1 (en)
CN (1) CN102143741B (en)
BR (1) BRPI0823082B8 (en)
ES (1) ES2560533T3 (en)
MX (1) MX2011001594A (en)
WO (1) WO2010030054A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345646A1 (en) * 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
KR101138565B1 (en) * 2010-03-25 2012-05-10 동아제약주식회사 Composition for the prevention or treatment of obesity or lipid related metabolic deseases
WO2013186766A1 (en) * 2012-06-11 2013-12-19 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
CN103626636B (en) * 2013-11-06 2015-04-08 中国科学院南海海洋研究所 Novel streptomycete sesquiterpene triol A and preparation method and application
JP2017531469A (en) 2014-09-26 2017-10-26 ザ プロクター アンド ギャンブルカンパニー Products containing malodor reducing materials
CN108369223B (en) * 2015-12-30 2021-07-06 雀巢产品有限公司 Method for determining lean body mass
CN108697599A (en) 2016-03-24 2018-10-23 宝洁公司 Include the hair care composition of malodor reduction composition
KR101674622B1 (en) * 2016-07-07 2016-11-09 국민대학교산학협력단 Novel Use of Sesquiterpene Derivatives
KR102061933B1 (en) 2017-06-23 2020-01-02 연세대학교 산학협력단 Composition comprising sesquiterpene derivatives or as active ingredients for muscle strengthening, development, differentiation, regeneration or inhibiting muscle atrophy
WO2019074993A1 (en) 2017-10-10 2019-04-18 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
US10792384B2 (en) 2017-12-15 2020-10-06 The Procter & Gamble Company Rolled fibrous structures comprising encapsulated malodor reduction compositions
WO2021034111A1 (en) * 2019-08-20 2021-02-25 엠에프씨 주식회사 Novel sesquiterpene derivative and use thereof
CN114746153A (en) 2019-12-06 2022-07-12 宝洁公司 Sulfate-free compositions with enhanced scalp active deposition
CN115151310A (en) 2020-02-27 2022-10-04 宝洁公司 Sulfur-containing anti-dandruff compositions with enhanced efficacy and aesthetics
CN112245416A (en) * 2020-11-17 2021-01-22 广西馨海药业科技有限公司 Application of pinnatifone A in preparation of drugs with sedative and hypnotic effects and drug composition
MX2023005963A (en) 2020-12-04 2023-06-07 Procter & Gamble Hair care compositions comprising malodor reduction materials.
KR102383733B1 (en) * 2021-02-18 2022-04-11 고려대학교 산학협력단 Pharmaceutical composition for preventing or treating sarcopenia comprising sesquiterpene derivatives
US20220378684A1 (en) 2021-05-14 2022-12-01 The Procter & Gamble Company Shampoo Compositions Containing a Sulfate-Free Surfactant System and Sclerotium Gum Thickener
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
CN115282131B (en) * 2022-07-26 2023-10-10 东莞广州中医药大学研究院 Pharmaceutical composition for treating non-alcoholic fatty liver and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007398A1 (en) * 1997-07-24 1999-02-18 Zografos-Dietetic Products S.A.C.I. Products from cypress and all relative coniferous trees and their pharmaceutical uses
JP2006241287A (en) * 2005-03-02 2006-09-14 Suntory Ltd Composition having lipid metabolism-improving effect
WO2007066305A1 (en) * 2005-12-09 2007-06-14 Zelpy 2549 (Pty) Limited Compositions comprising sesquiterpene compounds for use in the prophylaxis or treatment of pain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US702722A (en) 1901-11-21 1902-06-17 William Gorman Heating-furnace.
JP3113759B2 (en) * 1993-05-17 2000-12-04 花王株式会社 Sesquiterpene derivatives
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
FR2773079B1 (en) 1997-12-30 2002-05-17 Itzik Harosh TREATMENT TARGET FOR ATHEROSCLEROSIS, OBESITY AND TYPE II DIABETES
RU2228927C2 (en) 1999-07-28 2004-05-20 Орто-Макнейл Фармасьютикал, Инк. Derivatives of amines or amides, pharmaceutical composition based on thereof and method for antagonizing receptor y5 of neuropeptide npy
JP2001247461A (en) * 2000-03-03 2001-09-11 Zenyaku Kogyo Kk Prophylactic or ameliorant for diabetes
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050271755A1 (en) * 2004-05-12 2005-12-08 Ilya Raskin Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals
KR100711028B1 (en) * 2005-07-13 2007-04-24 한국생명공학연구원 Composition for the prevention and treatment of obesity and type 2 diabetes comprising a Juniperus chinensis extract or cedrol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007398A1 (en) * 1997-07-24 1999-02-18 Zografos-Dietetic Products S.A.C.I. Products from cypress and all relative coniferous trees and their pharmaceutical uses
JP2006241287A (en) * 2005-03-02 2006-09-14 Suntory Ltd Composition having lipid metabolism-improving effect
WO2007066305A1 (en) * 2005-12-09 2007-06-14 Zelpy 2549 (Pty) Limited Compositions comprising sesquiterpene compounds for use in the prophylaxis or treatment of pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200667, Derwent World Patents Index; AN 2006-640821, XP002663412 *
See also references of WO2010030054A2 *

Also Published As

Publication number Publication date
CN102143741A (en) 2011-08-03
BRPI0823082A2 (en) 2015-06-16
EP2331089B1 (en) 2015-12-16
CN102143741B (en) 2013-09-11
BRPI0823082B8 (en) 2021-05-25
KR100905419B1 (en) 2009-07-02
EP2331089A2 (en) 2011-06-15
MX2011001594A (en) 2011-06-27
US8481592B2 (en) 2013-07-09
US20120129924A1 (en) 2012-05-24
BRPI0823082B1 (en) 2019-02-26
WO2010030054A2 (en) 2010-03-18
JP2012502094A (en) 2012-01-26
WO2010030054A3 (en) 2010-07-15
JP5435375B2 (en) 2014-03-05
ES2560533T3 (en) 2016-02-19

Similar Documents

Publication Publication Date Title
EP2331089A4 (en) Uses of sesquiterpene derivatives
HK1256310A1 (en) N-sulphonylpyrrole derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (en) Dihydropyrimidopyrimidine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
EP2291078A4 (en) Oxazolobenzimidazole derivatives
ZA201102449B (en) Morpholinopurine derivatives
GB201105991D0 (en) Anti-tumoural effects of cannabinoid combinations
EP2279532A4 (en) Oxazolobenzimidazole derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL208336A0 (en) Pyrisazinone derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
PL2133419T3 (en) Uses of cyanophycin beta-dipeptides
IL210613A0 (en) Novel acylaminobenzamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
EP2231687A4 (en) Novel derivatives of acyl cyanopyrrolidines
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
ZA201105050B (en) Quinazolinamide derivatives
HK1160925A1 (en) Use of athepsin
EP2292613A4 (en) Dihydroindolinone derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20111123

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/22 20060101ALI20111116BHEP

Ipc: A61P 3/10 20060101ALI20111116BHEP

Ipc: A61P 3/00 20060101ALI20111116BHEP

Ipc: A61P 3/04 20060101ALI20111116BHEP

Ipc: A61K 31/19 20060101AFI20111116BHEP

17Q First examination report despatched

Effective date: 20140715

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150526

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 765178

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160115

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008041619

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2560533

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160219

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20151216

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 765178

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160317

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160416

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160418

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008041619

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

26N No opposition filed

Effective date: 20160919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161020

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: BELLERIVESTRASSE 203 POSTFACH, 8034 ZUERICH (CH)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151216

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20221020

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221031

Year of fee payment: 15

Ref country code: GB

Payment date: 20221024

Year of fee payment: 15

Ref country code: ES

Payment date: 20221118

Year of fee payment: 15

Ref country code: DE

Payment date: 20221026

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221027

Year of fee payment: 15